Nephrology and Hypertension

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Cardiovascular Effects of Adderall in Healthy Young Adults

   Rochester, Minn.

   The purpose of this study is to determine blood pressure and heart rate changes (hemodynamic changes) in healthy adults after taking one dose of prescription medication Adderall 25 mg orally, and comparing the results to those of  a placebo pill. 

2. Cystic Kidney and Liver Disease Biobank

   Rochester, Minn.

    

   This research study is being done to create a collection of biospecimens (blood, urine, cyst fluid, bile, kidney or liver tissue, etc.) that can be used to facilitate the conduction of research on polycystic kidney and/or liver disease.

3. A Study to Evaluate Effectiveness of Preventing Urinary Stones With Hydration

   Rochester, Minn.

   The purpose of this trial is to investigate the impact of increased fluid intake and increased urine output on the recurrence rate of urinary stone disease (USD) in adults and children. The primary aim of the trial is to determine whether a multi‐component program of behavioral interventions to increase fluid intake will result in reduced risk of stone disease progression over a 2‐year period.

4. A Study to Evaluate the Implications of the Human Microbiota for Health and Disease

   Rochester, Minn.

   The primary purpose of this study is to examine the human microbiota in healthy subjects.

    

5. Neural Circulatory Control and SUDEP Risk.

   Rochester, Minn.

   The investigators believe epilepsy alters the way the body controls blood pressure, heart rate and breathing, and these changes increase the risk of sudden unexpected death in patients with epilepsy (SUDEP). SUDEP-7 is a risk scoring tool which may correlate with these changes to the heart and blood vessels. This research study measures those differences which may help identify new markers to help predict those patients at greatest risk in the future.

6. Cardiovascular Effects of Energy Drinks in Healthy Adults

   Rochester, Minn.

   This study is being done to look at the cardiovascular response, if any, to intake of commercially available energy drink. We hypothesize that energy drink consumption compared to a control drink in healthy adults alters the cardiovascular hemodynamic system.

7. A Study of Quality of Life and Pain Control Before and After Endovascular Renal Denervation in Individuals with Refractory Kidney Pain

   Rochester, Minn.

   The purpose of this study is to examine patient reported outcomes including pain, quality of life, depression and impact on kidney blood flow before and after procedure to destroy the pain sensory nerves of the kidneys in patients with untreatable one or two sided kidney pain.

8. Genetic Markers of Cardiovascular Disease in Epilepsy

   Rochester, Minn.

   Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood but can be due to underlying conditions which affect the heart and brain, which may lead to dangerous heart rhythms and death. Some of these conditions which affect heart and brain have an identifiable genetic cause. This study aims to identify known genetic causes of heart rhythm and sudden death related disorders in patients with epilepsy.

9. A Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients

   Rochester, Minn.

   The primary purose of this study is to determine the effect of venglustat on the rate of total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) decline in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD).

10. A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

    Rochester, Minn.

    The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These patients are at high risk for progression of kidney disease, which can result in end-stage renal failure.